Acellular plasma and uses thereof for tissue regeneration
Patent Information
- Authority / Receiving Office
- EP · EP
- Patent Type
- Applications
- Current Assignee / Owner
- KAMADA LTD
- Filing Date
- 2024-08-07
- Publication Date
- 2026-06-17
AI Technical Summary
Current methods for tissue regeneration using blood-derived products are limited by the need for cellular components, which pose risks such as blood-borne viral disease transmission and logistical challenges for large-scale manufacturing. Additionally, these methods often require active viral reduction steps that are costly and limited in effectiveness.
The development of a plasma-derived pseudoserum, which is derived from acellular plasma partially depleted of fibrinogen and fibrin, and is characterized by its tolerance to viral inactivation, hypo-inflammatory cytokine and growth factor content, and superior biological activity promoting cell proliferation, resistance to stress, and cell migration.
The pseudoserum achieves effective tissue regeneration by enhancing cellular proliferation, increasing resistance to hyperosmolar stress, and promoting favorable cytokine release profiles, all while being tolerant to viral inactivation and hypo-inflammatory, thus addressing the limitations of existing methods.
Smart Images
Figure IL2024050794_13022025_PF_FP_ABST